Opinion of the Transparency Council – telmisartan + amlodipine besylate + hydrochlorothiazide
At its meeting on 13 May 2025, the Transparency Council adopted opinion No. 83/2025 on the inclusion of medicinal products containing the active substances telmisartan + amlodipine besylate + hydrochlorothiazide in the reimbursement scheme for indications for use or dosage or method of administration other than those specified in the Summary of Product Characteristics, i.e. hypertension